Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Expands By 5.7%

Fractyl Health, Inc. (NASDAQ:GUTS) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 2,430,000 shares, an increase of 5.7% from the July 15th total of 2,300,000 shares. Currently, 12.2% of the company’s stock are short sold. Based on an average trading volume of 244,600 shares, the days-to-cover ratio is currently 9.9 days.

Fractyl Health Trading Up 1.7 %

GUTS traded up $0.04 during midday trading on Friday, hitting $2.39. The company had a trading volume of 227,719 shares, compared to its average volume of 292,404. The stock’s 50 day simple moving average is $4.06. Fractyl Health has a 52 week low of $1.74 and a 52 week high of $14.50. The company has a current ratio of 9.38, a quick ratio of 9.37 and a debt-to-equity ratio of 0.34.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.10. The firm had revenue of $0.04 million during the quarter. Analysts predict that Fractyl Health will post -2.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds and other institutional investors have recently modified their holdings of GUTS. M28 Capital Management LP bought a new position in shares of Fractyl Health in the 1st quarter worth $13,735,000. American International Group Inc. bought a new position in shares of Fractyl Health in the first quarter valued at $9,911,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after buying an additional 25,829 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Fractyl Health during the second quarter valued at about $61,000. Finally, Rhumbline Advisers bought a new stake in shares of Fractyl Health during the second quarter worth about $32,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.